TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06203600: Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

Sponsor: National Cancer Institute (NCI) · Phase: PHASE2/PHASE3 · Area: ONCOLOGY · Target Enrollment: 224 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$4,340,028

Rescue Site Savings

+$2,874,564

Unlock Full NCT06203600 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06203600 Rescue Dossier →